- Patent Title: N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
-
Application No.: US16622057Application Date: 2018-06-12
-
Publication No.: US11253516B2Publication Date: 2022-02-22
- Inventor: Kwangho Lee , Inji Shin , Gildon Choi , Chong Hak Chae , Hyeon Jeong Choe , Myoung Eun Jung , Byeong Uk Jeon , Byoung Chul Cho , Chae Won Park , Hwan Kim , Krishna Babu Duggirala
- Applicant: Korea Research Institute of Chemical Technology
- Applicant Address: KR Daejeon
- Assignee: Korea Research Institute of Chemical Technology
- Current Assignee: Korea Research Institute of Chemical Technology
- Current Assignee Address: KR Daejeon
- Agency: Foley Hoag LLP
- Agent David P. Halstead
- Priority: KR10-2017-0073907 20170613,KR10-2017-0146241 20171103
- International Application: PCT/KR2018/006644 WO 20180612
- International Announcement: WO2018/230934 WO 20181220
- Main IPC: A61K31/506
- IPC: A61K31/506 ; A61K31/5377 ; A61K45/06 ; A61P35/00 ; C07D413/12 ; C07D401/14 ; C07D413/14 ; C07D401/12

Abstract:
The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.
Public/Granted literature
Information query
IPC分类: